MAP1B expression was found to be negatively correlated with relapse-free survival with statistical significance in all breast cancer subtypes, but the difference in survival time between the high and low groups was modest (Fig. 1 D, upper left; hazard ratio [HR] = 1.15). This evidence concerns the gene MAP1B and breast carcinoma.